Eli Lilly (LLY) shares are inching higher on Thursday morning after the pharmaceutical behemoth announced a definitive agreement to acquire AtaiBeckley (ATAI) for $2.8 billion in cash.
The deal, which could be worth up to $3.8 billion including performance milestones, represents LLY’s first major move into a brand-new therapeutic market – psychedelic medicine.